Results 311 to 320 of about 5,538,805 (353)

A Phase 3 Multicenter, Double‐Blind Study Comparing Efficacy, Safety, Immunogenicity, and Pharmacokinetics of Alkem's Biosimilar Teriparatide Versus Reference Teriparatide in Postmenopausal Osteoporosis

open access: yesAGING MEDICINE, EarlyView.
This phase III study demonstrated that Alkem's biosimilar teriparatide is noninferior to reference teriparatide in improving bone mineral density at the lumbar spine and femoral neck in postmenopausal osteoporosis patients, with comparable safety, pharmacodynamics, and immunogenicity profiles over 48 weeks of treatment.
Nitin Kapoor   +18 more
wiley   +1 more source

Cell- and Pathway-Specific Disruptions in the Accumbens of Fragile X Mouse. [PDF]

open access: yesJ Neurosci
Giua G   +5 more
europepmc   +1 more source

Establishment of a Nonradioactive Molecular Diagnosis of Fragile-X Syndrome

open access: green, 2000
Zehra Oya Uyguner   +5 more
openalex  

In Utero Alcohol and Unsuitable Home Environmental Exposure Combined with <i>FMR1</i> Full Mutation Allele Cause Severe Fragile X Syndrome Phenotypes. [PDF]

open access: yesInt J Mol Sci
Winarni TI   +9 more
europepmc   +1 more source

Fragile X syndrome

Nature Reviews Disease Primers, 2017
Fragile X syndrome (FXS) is the leading inherited form of intellectual disability and autism spectrum disorder, and patients can present with severe behavioural alterations, including hyperactivity, impulsivity and anxiety, in addition to poor language development and seizures.
Hagerman, Randi J.   +10 more
openaire   +5 more sources

Home - About - Disclaimer - Privacy